home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

The 2014 Alzheimer's Disease Congress

  February 12, 2014  

EuroSciCon, Cineworld: The O2, Peninsula Square, London, SE10 0DX, United Kingdom
Monday, 23 June 2014 09:00 - Wednesday, 25 June 2014 17:00

This three day event will discuss aspects of  Alzheimer's Disease development and treatment in an informal academic setting. This year there are three main topics for discussion
  1. Biomarker Discovery and Assay Development 
  2. Prevention Strategies and Vaccine Development 
  3. Drug Discovery and Development 

With plenty of opportunity  for networking and debate, this informal international  meeting will bring you up to date with current research and thinking regarding Alzheimer's Disease.



Day 1: Biomarker Discovery and Assay Development
Currently, there are many biomarkers for diagnosis of Alzheimer's disease. However most of them do not provide consistent results.  This session will discuss current research aimed at obtaining reliable biomarkers which could be used to diagnose Alzheimer's disease at very early stage and also to provide objective and reliable measures of disease progress.

Day 2:  Prevention Strategies and Vaccine Development 
This session will discuss current research into Alzheimer's Disease prevention including vaccine development. There will be plenty of opportunity for discussion and debate.

Day 3:  Drug Discovery and Development
There are currently no treatments that will stop or reverse the progress of Alzheimer’s disease. With an aging population and increasing number of people with Alzheimer’s, the need to develop ways to halt and treat the disease have become paramount.  This session will discuss current research into Alzheimer’s drug discovery and development including analysis of current clinical trials

Talks include 
  • SemiAlloGeneic Vaccines for Alzheimer's Disease, Professor Mark S. Kindy, Medical University of South Carolina, USA
  • New era in AD drug design: intracellular and exosomal targets, Dr Botond Penke, Professor,  University of Szeged, Department of Medical Chemistry, Hungary
  • Why have we failed to cure AD?, Professor Amos Korczyn, Professor Emeritus, Tel-Aviv University Medical School, Israel
  • What did we learn from the first clinical trial of Aβ immunotherapy?, Dr Delphine Boche, Senior lecturer (Associate Professor), University of Southampton, UK
  • Discovery of multitarget lead candidates to tackle the multifactorial nature of Alzheimer's disease, Professor Andrea Cavalli, University of Bologna and Italian Institute of Technology, Italy
  • The role of herpes simplex virus type 1 in Alzheimer’s disease, Professor Ruth Frances Itzhaki, University of Manchester, Manchester, UK
  • Is AD A Medical Notion of Dementia Worth Keeping in Neuroscience?, Professor Fred C. C. Peng, Ph.D. Affiliation: Department of Neurosurgery and Neurological Institute, Taipei Veterans General Hospital, Taiwan
  • The biomarkers assessment in a Memory Clinic : is there any added value?, Professor Adrian Ivanoiu, MD, PhD, neurologist, Saint Luc University Hospital & Institute of Neuroscience, Catholic University of Louvain, Brussels, Belgium
  • How to Prevent Dementia and Alzheimer's, Dr Allen J. Orehek,Innovator/Physician, Dementia Prevention Center, USA
  • Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease, Dr Željko M. Svedružić,Assistant Professor, Faculty of Medicine, and Department of Biotechnolgy, Univeristy of Rijeka, Croatia
  • Regulatory T cells as new targets for immunotherapy in Alzheimer's disease?, Dr Guillaume Dorothee, Hôpital Saint-Antoine, Paris, France
  • Activities of daily living: a new approach to discovering Alzheimer therapies, Dr Robert Deacon, UK
  • Cerebrospinal fluid Presenilin-1: a potential new biomarker for Alzheimer’s disease, Dr Javier Sáez-Valero, Professor and Group Leader, Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, & Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain
  • Investigation of novel functional and metabolic MRI biomarkers for  the preclinical assessment of taupathology in AD, Dr Niall Colgan, Research Associate, UCL Centre for Advanced Biomedical Imaging, London UK
  • Eye movement biomarkers in Alzheimer’s disease, Dr Olivier Coubard,The Neuropsychological Laboratory, Paris, France
  • Alzheimer's disease in Down's syndrome -an ideal model for biomarker discovery? Dr Shahid ZamanAffiliated Lecturer & Consultant Psychiatrist, University of Cambridge & NHS, UK
  • Going beyond Preclinical Animal Models : Quantitative Systems Pharmacology to support Alzheimer’s Disease Research & Development Dr Hugo Geerts, Chief Scientific Officer,  In Silico Biosciences, USA
  • CSF biomarker changes precede symptom onset of mild cognitive impairment. Dr Abhay Moghekar, Asst. Professor of Neurology,  Johns Hopkins University School of Medicine, USA

This will be a paperless meeting, please print out the agenda and abstract book before you come or download the pdf onto your computer or smartphone.
Pdfs of our agendas and abstract books can be found at http://lifescienceevents.com/events  
The deadline for abstract submissions for oral presentation is March 10th 2014. Abstracts for poster presentation only can be submitted up to two weeks before the event.  
You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf 

 Keywords: biomarkers, biomarker,neurochemical, Alzheimer's disease,blood plasma,Amyloid beta,BACE1,Soluble Aβ precursor protein,Beta amyloid antibodies, Amyloid hypothesis; Prevention; Brain Aging; Dementia; , biomarkers,  mild cognitive impairment, Memory Clinic, Tau, MRI, biomarker, imaging, Alzheimers, , Cerebrospinal fluid, Biomarker, Presenilin, γ-Secretase,Amyloid beta,,Immunotherapy,Passive immunotherapy, MPC-7869,γ-secretase,AL-108,PBT2 ,Immunotherapy,Passive immunotherapy,AN-1792,Gamma secretase,LY451039,Tarenflurbil,PBT2 ,Simvastatin,Allopregnanolone,Angiotensin ,Cannabinoids,Methylthioninium chloride, immunotherapy, neuroinflammation, neurodegeneration, γ-secretase, amyloid, enzyme-mechanisam, FAD mutations, Burrowing, hippocampus, nesting, hoarding, marble, dementia, brain ageing, alzheimer's, intracellular Abeta, prionoid, exosome, cell-to-cell spreading, Down's syndrome, Amyloid, [11C]-PiB-PET, Alzheimer's disease; herpes simplex virus type 1; beta amyloid; AD-like tau; antiviral agents, Fischer's Disease, Dementia, MCI, Auguste's brain atrophy, Translational disconnect, Systems Pharmacology, Trial Failure analysis, Alzheimer's disease, adaptive immunity, regulatory T cells, neuroinflammation, immunotherapy, Alzheimer's disease; Biomarkers; Cerebrospinal fluid, Mild cognitive impairment

Organized by: Euroscicon
Invited Speakers:

Amos Korczyn Graduated from the Hebrew University–Hadassah Medical School in Jerusalem MD and MSc in pharmacology (cum laude) in 1966.  Trained in neurology at Beilinson Hospital and at the National Hospital, Queen Square, London.  He was the Chairman of Neurology, Tel-Aviv Medical Center, 1981-2002, and incumbent of the Sieratzki Chair of Neurology at Tel-Aviv University, 1995-2010.  Has a particular interest in neurodegenerative diseases,  and authored or co-authored over 600 articles, as well as book chapters. Professor Korczyn is the Chairman of the Scientific Administrative Board of the Israeli Alzheimer's disease association (EMDA), and member of the SAB of Alzheimer Disease International.

Adrian Ivanoiu is a clinical neurologist and neuroscientist. He defended a doctoral thesis on cognitive and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment and Alzheimer disease. He collaborated with Professor John Hodges at MRC Cognition and Brain Sciences Unit, Cambridge, UK. He is in charge of the Memory Clinic of Saint Luc University Hospital and leads a research group at the Institute of Neuroscience of the Catholic University of Louvain, Brussels, Belgium. Professor Ivanoiu is interested in the evaluation of cognitive and biological markers of neurodegeneration : episodic memory, CSF, MRI, PET scan.

Niall Colgan is a Senior Research Associate in the Centre for Advanced Biological Imaging in the College of Medicine at University College London. His research is in the area of preclinical biomarkers in Alzheimer’s disease and drug discovery and his specialty area is Magnetic resonance imaging, metabolism and experimental therapeutics. Prior to this he was a lecturer in Medical Imaging (MRI) in the College of Medicine at Swansea University and worked in Trinity College Dublin in MRI related to traumatic brain injury, University College Dublin in neurological MRI. His primary research focus is magnetic resonance imaging, particularly MR metabolite imaging and diffusion MRI.

Javier Sáez-Valero is a Lecturer in Biochemistry and Molecular Biology at the Miguel Hernández University of Spain, leading a group at the Instituto de Neurociencias, the first Spanish research institute devoted to the better knowledge of the nervous system in health and disease. His group is also member of The Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), a “networked” institute that represent the Spanish initiative to combat neurodegenerative diseases, bringing together the best basic and clinical neuroscience research groups. Sáez-Valero aims to introduce a line of research into Alzheimer’s disease (AD) and dementia that originated from a basic point of view but relevant to the development of clinical-diagnostic applications.

Mark Kindy is a neuroscientist and Professor in the Department of Neurosciences at the Medical University of South Carolina and a Senior Research Career Scientist at the Ralph H. Johnson VA Medical Center in Charleston, SC.  He received his BS from the University of Massachusetts in Zoology and PhD from Boston University School of Medicine in Biochemistry.  He was a postdoctoral fellow at the Salk Institute.  He started his faculty career at the University of Kentucky School of Medicine in the Department of Biochemistry and the Center on Aging.  His area of expertise is neurodegenerative disorders.

Delphine Boche is a Senior Lecturer in Clinical Neurosciences at the University of Southampton, UK. Her main research is to understand the role of neuroinflammation in relation with the neuropathology in neurological diseases and has now developed an expertise in clinical neuroimmunopathology.  She obtained her PhD in 1997 from the University Paris-VI where she investigated the pathophysiology of the HIV-dementia using animal models. Then, she moved to Southampton to study the neuroinflammation in neurodegenerative diseases using mouse models before joining the Faculty of Medicine to explore the pathophysiology of Alzheimer’s disease following the active Ab42 immunotherapy.

Botond Penke was born in Hungary, studied biology and chemistry in Budapest. PhD: 1968, Szeged University. Post-doctoral years: Max Planck Institute for Med. Research Heidelberg, and Gőttingen, Centre Energie Nucléaire (CEN-CEA) Saclay, The Salk Institute San Diego. Associate professor at the Szeged University (1980), full professor and institute director (1995-2005). Leader of the Neurobiological Research Centre at Szeged (2006-2012). Research topics: synthesis of peptide hormones; immunhistochemical detection of neurotransmitters; the mechanism of action of amyloid proteins; AD drug development.

Allen J. Orehek, MD is an innovator and physician whose unique talent is the prevention of dementia and Alzheimer's. Board certified in Internal Medicine and Pediatrics, Orehek's fresh new concepts are designed for the motivated individual. It is a method that has resulted in stopping progression of dementia for many and providing reversal for some. Works include: 'The Micron Stoke Hypothesis of Alzheimer's Disease and Dementia' (Medical Hypotheses 78 (2012) 562-570).Prevention is Difficult - But Possible on amazon.com.

Robert Deacon obtained his first degree in pharmacology at the University of Wales, where he also studied psychopharmacology for his doctorate. After learning stereotaxic surgery at Bradford University, he spent 8 years in the pharmaceutical industry (Roussel Laboratories) before starting research at Oxford University in 1991. He has worked extensively on the hippocampus and its function in mice and rats, and about 10 years ago formulated the novel idea that the hippocampus was vital for mediating species-typical behaviours, equivalent to rodent ADL, and proposed that these ADL tests could be used to provide an alternative approach in the hunt for new AD therapies.

Željko M. Svedružić is currently Assistant professor at Department of Biotechnology and at Faculty of Medicine, University of Rijeka, Croatia. Dr Svedružić got his training in γ-secretase and the related drug-development efforts, working as a senior scientist on a collaborative project between world leading expert Professor Bart de Strooper and Drug Hunting Team of Eli Lilly Company. Dr Svedružić earned his Ph.D. in enzymology from Oklahoma State University, and did his postdoctoral research at University of California at Santa Barbara, Duke University, and Washington State University.

Additional Confirmed Speakers


Dr. Kailas Dashrath Sonawane, Head Department of Microbiology, Shivaji University, Maharashtra, India 


Deadline for Abstracts: The deadline for abstract submissions for oral presentation is March 10th 2014.

Click here to register online


E-mail: enquiries@euroscicon.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.